Cargando…
Comparison of botulinum toxins for treatment of movement disorders: real-world utilization and cost analysis in a national Medicare population
BACKGROUND: The Centers for Medicare & Medicaid Services (CMS) is the single largest payer for health care in the United States and the largest payer by spending globally. Medicare Part B, with more than 50 million beneficiaries, currently has no broad mechanisms in place for promoting cost-effe...
Autores principales: | Kazerooni, Rashid, Watanabe, Jonathan H |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Academy of Managed Care Pharmacy
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394205/ https://www.ncbi.nlm.nih.gov/pubmed/33511895 http://dx.doi.org/10.18553/jmcp.2021.20346 |
Ejemplares similares
-
Use of botulinum toxin for movement disorders
por: Camargo, Carlos Henrique Ferreira, et al.
Publicado: (2019) -
Botulinum Toxin in Movement Disorders: An Update
por: Anandan, Charenya, et al.
Publicado: (2021) -
History of Botulinum Toxin Treatment in Movement Disorders
por: Jabbari, Bahman
Publicado: (2016) -
Experiences on The Administration of Botulinum Toxin in Movement Disorders
por: Tuğan Yıldız, Buket, et al.
Publicado: (2021) -
Guidelines for the use of botulinum toxin in movement disorders and spasticity
por: Jabeen, Afshan, et al.
Publicado: (2011)